BioventusBVS +0.51%66 OCF Yield % is 15.54 as of Jun. 27, 2026, which is 189% above its 10-year median of 5.37. GuruFocus rates BVS with a GF Score™ of 66/100 and a GF Value™ of $6.79 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Bioventus ranks better than 93.43% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Bioventus OCF Yield % Related Terms
Bioventus OCF Yield % Historical Data
* Premium members only.
The historical data trend for Bioventus's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bioventus's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioventus OCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bioventus's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Bioventus's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioventus (BVS) has a OCF Yield % of 15.54 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bioventus and its competitors. This is 189% above median its historical median of 5.37. According to the industry distribution chart, Bioventus ranks #56 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 6.6%.
Is Bioventus' OCF Yield % too high?
Bioventus' current OCF Yield % of 15.54 is 189% above median its 10-year median of 5.37. The Medical Devices & Instruments industry median OCF Yield % is 1.79. Bioventus' value of 15.54 is 770.6% above this industry median. Based on the distribution chart, Bioventus ranks #56 out of 852 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bioventus has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bioventus' OCF Yield % compare to NPCE and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Bioventus ranks #56 out of 852 companies for OCF Yield %. This places Bioventus in the top 7% of its industry — outperforming the majority of peers. The industry median OCF Yield % is 1.79. Bioventus' value of 15.54 is 770.6% above this benchmark. While the company's 10-year median is 5.37 vs. the industry median of 1.79, Bioventus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Devices & Instruments company?
The median OCF Yield % among Medical Devices & Instruments companies is 1.79, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioventus's current OCF Yield % of 15.54 is 770.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Bioventus and its competitors. For the Medical Devices & Instruments industry, the median OCF Yield % is 1.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioventus's current OCF Yield % is 15.54, which is 189% above median its own 10-year median of 5.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioventus stock overvalued right now?
Based on GuruFocus' analysis, Bioventus (BVS) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.79, compared to a current price of $9.78 — trading 44% above its estimated fair value. The current OCF Yield % is 15.54, which is 189% above median its 10-year median of 5.37 and 770.6% above the Medical Devices & Instruments industry median of 1.79. Bioventus' overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Bioventus (BVS), the current OCF Yield % is 15.54 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioventus (BVS) Overvalued in 2026?
Based on GuruFocus' analysis, Bioventus stock appears to be overvalued.
The current stock price of $9.78 is trading 44% above its estimated GF Value™ of $6.79.
GuruFocus considers Bioventus to be Significantly Overvalued.
Key valuation signals for BVS:
OCF Yield %: 15.54 (189% above median its 10-year median of 5.37)
GF Value™: $6.79 vs. price of $9.78 (44% above fair value)
Industry Position: 770.6% above the Medical Devices & Instruments median (#56 of 852)
No single metric tells the full story. See the BVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
66GF Score
Get the complete analysis for BVS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BVS has been successfully added to your 
